Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger
Amid Continued Obesity Lag
The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.
